2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis Rituximab, Ocrelizumab, Fexofenadine - Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 3 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 600 | 2021-04-28 | 2026-08-17 |
| Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease Rituximab, Ocrelizumab - Relapsing Remitting Multiple Sclerosis | Phase 3 | Active not recruiting | Haukeland University Hospital | 214 | 2020-11-02 | 2025-06-27 |
Multiple Sclerosis, Relapsing-Remitting (2) · Multiple Sclerosis, Chronic Progressive (1)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Multiple Sclerosis (2) · Nervous System Diseases (2) · Chronic Disease (1) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Rituximab (2) · ocrelizumab (2) · Acetaminophen (1) · Methylprednisolone (1) · fexofenadine (1)
Copenhagen University Hospital, Rigshospitalet (1) · Haukeland University Hospital (1)
Denmark (1) · Norway (1) · Sweden (1)
Jeppe Romme Christensen, MD, PhD (1) · Kjell-Morten Myhr, MD (1)